Expand ARTL Menu
ARTL MENU

ARTL Latest Press Releases

-- April 7, 2026 --

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements Globe Newswire 7:50 AM

-- March 30, 2026 --

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 4:46 PM

-- March 27, 2026 --

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 10:40 AM

-- March 25, 2026 --

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments Globe Newswire 4:05 PM
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength Globe Newswire 7:31 AM

-- March 18, 2026 --

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum Globe Newswire 10:41 AM
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study Globe Newswire 8:07 AM
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients Globe Newswire 7:41 AM

-- March 6, 2026 --

Artelo Biosciences Announces Reverse Stock Split Globe Newswire 8:00 AM

-- February 24, 2026 --

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results Globe Newswire 8:00 AM

-- December 23, 2025 --

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate Globe Newswire 9:00 AM

-- December 3, 2025 --

Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes